Innovent Biologics Inc
HKEX:1801
Innovent Biologics Inc
Revenue
Innovent Biologics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥6.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
266%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥9.6B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
S
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Revenue
¥7.6B
|
CAGR 3-Years
41%
|
CAGR 5-Years
32%
|
CAGR 10-Years
27%
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥49.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
65%
|
CAGR 10-Years
50%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥1.9B
|
CAGR 3-Years
51%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
See Also
What is Innovent Biologics Inc's Revenue?
Revenue
6.2B
CNY
Based on the financial report for Dec 31, 2023, Innovent Biologics Inc's Revenue amounts to 6.2B CNY.
What is Innovent Biologics Inc's Revenue growth rate?
Revenue CAGR 5Y
266%
Over the last year, the Revenue growth was 36%. The average annual Revenue growth rates for Innovent Biologics Inc have been 17% over the past three years , 266% over the past five years .